Evidence map›Paper›PMID 34127005›Full record

ArticleJournal of nanobiotechnology2021

Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.

Xueyuan Yang, Weizhong Zhang, Wen Jiang, Anil Kumar, Shiyi Zhou, Zhengwei Cao, Shuyue Zhan, Wei Yang, Rui Liu, Yong Teng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Automated radiosynthesis of 1-(2-[Journal of labelled compounds & radiopharmaceuticals · 2023
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueyuan YangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Weizhong ZhangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Wen JiangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Anil KumarDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Shiyi ZhouDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Zhengwei CaoDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Shuyue ZhanDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Wei YangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Rui LiuDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Yong TengDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Jin XieDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA. jinxie@uga.edu.ORCID http://orcid.org/0000-0002-8915-6233

Funding

The development of novel radiation-sensitizer based on ultra-small carbon dotsR01CA247769 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, XIE, JIN · 2020 to 2024
$2.5M
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancerR01CA257851 · NCI · UNIVERSITY OF GEORGIA · PI KIM, WILLIAM Y., LI, ZIBO · 2021 to 2024
$2.1M
Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiationR01EB022596 · NIBIB · UNIVERSITY OF GEORGIA · PI XIE, JIN · 2017 to 2020
$1.9M
ATAD3A as a Novel Target in Head and Neck CancerR01DE028351 · NIDCR · EMORY UNIVERSITY · PI TENG, YONG · 2019 to 2023
$1.9M
Division of Materials Research NSF1552617NCI NIH HHS R01CA247769NCI NIH HHS R01 CA257851NCI NIH HHS R01CA257851NIBIB NIH HHS R01 EB022596NIBIB NIH HHS R01EB022596NIDCR NIH HHS R01 DE028351NIDCR NIH HHS R01DE028351
6 · The paper itself

Abstract

backgroundPhotodynamic therapy (PDT) may elicit antitumor immune response in addition to killing cancer cells. However, PDT as a monotherapy often fails to induce a strong immunity. Immune checkpoint inhibitors, which selectively block regulatory axes, may be used in combination with PDT to improve treatment outcomes. Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme and an important meditator of tumor immune escape. Combination therapy with PDT and IDO-targeted immune checkpoint blockage is promising but has been seldom been explored.

methodsHerein we report a composite nanoparticle that allows for simultaneous delivery of photosensitizer and IDO inhibitor. Briefly, we separately load ZnF

resultsOur results showed that PPF NPs can efficiently encapsulate both ZnF

Indexed as

AnimalsCD8-Positive T-LymphocytesCell Line, TumorDrug Delivery SystemsDrug LiberationEnzyme InhibitorsFerritinsHumansImidazolesImmunotherapyIndoleamine-Pyrrole 2,3,-DioxygenaseIsoindolesMiceMyeloid-Derived Suppressor CellsNanoconjugatesNanoparticles1-cyclohexyl-2-(5H-imidazo(5,1-a)isoindol-5-yl)ethanolEnzyme InhibitorsFerritinsImidazolesIndoleamine-Pyrrole 2,3,-DioxygenaseIsoindolesNanoconjugatesPhotosensitizing AgentsCancerFerritinIDOImmunotherapyNanoparticlesPhotodynamic therapy

Identifiers

PMID34127005
PMCPMC8201842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.